Osteoporosis testing and treatment remain low in both Traditional Medicare and Medicare Advantage
Osteoporosis International · 2025
DOI: 10.1007/s00198-024-07318-8 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Osteoporosis International, 2025. Verfasst von Tej D Azad und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Johns Hopkins University, Baltimore, MD, USA. tazad1@jhmi.edu. Hauptthemen laut MEDLINE: Osteoporosis, Medicare Part C, Medicare Part A, Medicare Part B. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben.
Abstract (Originalsprache)
Little is known regarding osteoporosis management between Traditional Medicare (TM) and Medicare Advantage (MA). MA beneficiaries had higher rates of osteoporosis testing and higher rates of osteoporosis drug treatment initiation rates. Following an osteoporotic fragility fracture, MA beneficiaries were more likely to be prescribed osteoporosis treatment. While osteoporosis testing and treatment initiation rates are low in both TM and MA, rates tended to be higher in MA. PURPOSE: Osteoporosis represents a substantial clinical challenge in the United States, particularly for older women, and requires effective care coordination. Medicare Advantage (MA) plans have financial incentives in the form of star ratings to improve osteoporosis testing and treatment. The objective of this study was to compare osteoporosis management practices between Traditional Medicare (TM) beneficiaries and MA female enrollees. METHODS: We conducted a cross-sectional study using a nationally representative 20% sample of 2017-2019 TM claims and MA encounter records. We identified 2,994,203 female TM beneficiaries and 1,924,132 MA enrollees. The exposure was enrollment in MA. The primary outcomes were the rates of guideline-recommended bone mineral density (BMD) testing and osteoporosis drug initiation following a new osteoporosis diagnosis and after a new osteoporotic fragility fracture. RESULTS: MA beneficiaries had higher unadjusted (22.0% vs. 19.8% in TM; P < 0.001) and adjusted rates (0.8 percentage points [p.p.] higher; P < 0.001) of BMD testing. Osteoporosis drug treatment initiation rates were higher in the MA cohort, both unadjusted (24.9% vs. 20.3% in TM; P < 0.001) and adjusted (4.0 p.p. higher; P < 0.001). Following an osteoporotic fragility fracture, MA beneficiaries were more likely to be prescribed pharmacologic treatment (28.7% vs. 21.1% in TM; P < 0.001), with an adjusted increase of 5.9 p.p (P < 0.001). CONCLUSION: Overall osteoporosis testing and treatment initiation rates in both TM and MA enrollees were low, with improved rates in MA compared to TM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurosurgery, Johns Hopkins University, Baltimore, MD, USA. tazad1@jhmi.edu.
- Hopkins Business of Health Initiative, Baltimore, MD, USA. tazad1@jhmi.edu.
- Hopkins Business of Health Initiative, Baltimore, MD, USA.
- Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA.
- Department of Clinical Pharmacy, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Aurora, CO, USA.
- Carey Business School, Johns Hopkins University, Baltimore, MD, USA.
Zitieren
APA
Azad, T. D., Wu, R. J., Anderson, K. E., Darden, M., & Jain, A. (2025). Osteoporosis testing and treatment remain low in both Traditional Medicare and Medicare Advantage. Osteoporosis International. https://doi.org/10.1007/s00198-024-07318-8
Vancouver
Azad TD, Wu RJ, Anderson KE, Darden M, Jain A. Osteoporosis testing and treatment remain low in both Traditional Medicare and Medicare Advantage. Osteoporosis International. 2025. doi:10.1007/s00198-024-07318-8
BibTeX
@article{Azad2025,
author = {Azad, Tej D and Wu, Rachel J and Anderson, Kelly E and Darden, Michael and Jain, Amit},
title = {Osteoporosis testing and treatment remain low in both Traditional Medicare and Medicare Advantage},
journal = {Osteoporosis International},
year = {2025},
doi = {10.1007/s00198-024-07318-8}
}
EUVIMED